{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:06:49Z","timestamp":1792822009801,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Amgen Asia Holding Limited"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Summary\n<\/jats:title>\n                <jats:p>This study assessed the cost-effectiveness of continued denosumab treatment, compared with discontinuation of denosumab after one dose, for the treatment of postmenopausal osteoporosis in Taiwan, using real-world fracture reduction effectiveness and cost data. Outcomes indicate that continued denosumab treatment produces an incremental cost-effectiveness ratio of USD $16,743 per QALY.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To evaluate the cost-effectiveness of continued denosumab use versus discontinuation after one dose, for the treatment of postmenopausal osteoporosis in Taiwan, using real-world fracture reduction effectiveness and cost data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A Markov cohort model was used to evaluate the lifetime costs and QALYs associated with continued denosumab treatment versus discontinuation of treatment after one dose. The evaluation was conducted from the perspective of Taiwan\u2019s healthcare system and used a discount rate of 3% per annum. The patient population consisted of postmenopausal women with osteoporosis with a mean age of 77\u00a0years who initiated denosumab treatment. Fracture reduction effectiveness data, baseline fracture rates, mortality data, and costs of fracture were informed by Taiwan\u2019s National Health Insurance Research Database.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Model outcomes showed that continued treatment with denosumab produced an expected gain of 0.042 QALYs and an incremental cost of USD $704, compared with discontinuation of denosumab after one dose. This corresponds to an incremental cost-effectiveness ratio of USD $16,743 per QALY gained. Probabilistic and scenario analysis showed that results are stable to variations in model assumptions and parameters.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In a real-world setting, at a cost per QALY threshold equivalent to gross domestic product per capita in 2020 in Taiwan (USD $30,038), continued treatment with denosumab in postmenopausal women with osteoporosis is cost-effective compared with treatment discontinuation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11657-021-01020-6","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T01:29:15Z","timestamp":1634088555000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Real-world cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in Taiwan"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3938-0920","authenticated-orcid":false,"given":"Ben","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward Chia-Cheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huang-tz","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Stollenwerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,12]]},"reference":[{"issue":"3","key":"1020_CR1","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.afos.2016.07.001","volume":"2","author":"EYN Cheung","year":"2016","unstructured":"Cheung EYN, Tan KCB, Cheung C-L, Kung AWC (2016) Osteoporosis in East Asia: Current issues in assessment and management. Osteoporosis and Sarcopenia 2(3):118\u2013133","journal-title":"Osteoporosis and Sarcopenia"},{"issue":"8","key":"1020_CR2","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756\u2013765","journal-title":"N Engl J Med"},{"issue":"S2213","key":"1020_CR3","first-page":"8587","volume":"17","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwi\u0144ski DE, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. The Lancet Diabetes & Endocrinology 17(S2213):8587","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"1020_CR4","unstructured":"Australian Government; Department of Health and Ageing (2011)\u00a0Australian public assessment report for denosumab. Available from:\u00a0https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-prolia.pdf. Accessed 11 Apr\u00a02021"},{"key":"1020_CR5","unstructured":"National Institute for Health and Clinical Excellence (2010)\u00a0Final appraisal determination Denosumab for the prevention of osteoporotic fractures in postmenopausal women.\u00a0Available from:\u00a0https:\/\/www.nice.org.uk\/guidance\/ta204\/documents\/osteoporotic-fractures-denosumab-final-appraisal-determination-document2. Accessed 11 Apr\u00a02021"},{"key":"1020_CR6","unstructured":"Food and Drug Administration; Ministry of Health and Welfare. Western medicine, medical equipment, cosmetics license inquiry.\u00a0Available from: https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=10000918. Accessed 25 Aug 2021"},{"key":"1020_CR7","unstructured":"National Health Insurance Administration; Ministry of Health and Welfare. Analysis of drug usage. Available from: https:\/\/www.nhi.gov.tw\/Content_List.aspx?n=5AA7CAFFF61CB16D&topn=5FE8C9FEAE863B46. Accessed 25 Aug 2021"},{"issue":"8","key":"1020_CR8","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.4065\/81.8.1013","volume":"81","author":"ES Siris","year":"2006","unstructured":"Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81(8):1013\u20131022","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"1020_CR9","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00198-010-1424-x","volume":"22","author":"B J\u00f6nsson","year":"2011","unstructured":"J\u00f6nsson B, Str\u00f6m O, Eisman JA, Papaioannou A, Siris ESE, Tosteson A, Kanis JA (2011) Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 22(3):967\u2013982","journal-title":"Osteoporos Int"},{"key":"1020_CR10","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40258-013-0047-8","volume":"11","author":"A Parthan","year":"2013","unstructured":"Parthan A, Kruse M, Yurgin N, Huang J, Viswanathan HN, Taylor D (2013) Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US. Appl Health Econ Health Policy 11:485\u2013497","journal-title":"Appl Health Econ Health Policy"},{"key":"1020_CR11","doi-asserted-by":"publisher","first-page":"627631","DOI":"10.1155\/2015\/627631","volume":"2015","author":"S Silverman","year":"2015","unstructured":"Silverman S, Agodoa I, Kruse M, Parthan A, Orwoll E (2015) Denosumab for elderly men with osteoporosis: a cost-effectiveness analysis from the US payer perspective. J Osteoporos 2015:627631","journal-title":"J Osteoporos"},{"issue":"5","key":"1020_CR12","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/13696998.2018.1445634","volume":"21","author":"N Raje","year":"2018","unstructured":"Raje N, Roodman GD, Willenbacher W, Shimizu K, Garc\u00eda-Sanz R, Terpos E, Kennedy L, Sabatelli L, Intorcia M, Hechmati G (2018) A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America. J Med Econ 21(5):525\u2013536","journal-title":"J Med Econ"},{"key":"1020_CR13","unstructured":"Lai E.C.-C., Lin T.-C., Lange J.L., Chen L., Wong I., Sing C.-W., Cheung C.-L., Shao S.-C., and Yang Y.-H.K., Effectiveness of denosumab for fracture prevention in real-world postmenopausal women with osteoporosis: retrospective cohort study. 2021, Amgen Inc.: Thousand Oaks, California, USA; OSIN-D-21\u201300989."},{"issue":"9","key":"1020_CR14","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00198-019-05064-w","volume":"30","author":"A Svedbom","year":"2019","unstructured":"Svedbom A, Hadji P, Hernlund E, Thoren R, McCloskey E, Stad R, Stollenwerk B (2019) Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom. Osteoporos Int 30(9):1745\u20131754","journal-title":"Osteoporos Int"},{"key":"1020_CR15","unstructured":"Taiwan Society for Pharmacoeconomics and Outcome Research (2014)\u00a0Health technology assessment guidelines. Available from: http:\/\/www.taspor.org.tw\/. Accessed 11 Apr\u00a02021"},{"issue":"1","key":"1020_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00198-008-0644-9","volume":"20","author":"O Str\u00f6m","year":"2009","unstructured":"Str\u00f6m O, Borgstr\u00f6m F, Kanis J, J\u00f6nsson B (2009) Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 20(1):23\u201334","journal-title":"Osteoporos Int"},{"issue":"7","key":"1020_CR17","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1080\/13696998.2020.1730381","volume":"23","author":"C Pongchaiyakul","year":"2020","unstructured":"Pongchaiyakul C, Nanagara R, Songpatanasilp T, Unnanuntana A (2020) Cost-effectiveness of denosumab for high-risk postmenopausal women with osteoporosis in Thailand. J Med Econ 23(7):776\u2013785","journal-title":"J Med Econ"},{"key":"1020_CR18","unstructured":"World Health Organization (2021)\u00a0International Statistical Classification of Diseases and Related Health Problems (ICD). Available from: https:\/\/www.who.int\/standards\/classifications\/classification-of-diseases. Accessed 25 Aug 2021"},{"issue":"2","key":"1020_CR19","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00198-015-3238-3","volume":"27","author":"C-Y Chang","year":"2016","unstructured":"Chang C-Y, Tang C-H, Chen K-C, Huang K-C, Huang K-C (2016) The mortality and direct medical costs of osteoporotic fractures among postmenopausal women in Taiwan. Osteoporos Int 27(2):665\u2013676","journal-title":"Osteoporos Int"},{"key":"1020_CR20","unstructured":"Statista. Taiwan: Inflation rate from 1984 to 2021. Available from: https:\/\/www.statista.com\/statistics\/727598\/inflation-rate-in-taiwan\/. Accessed 3 June 2020"},{"key":"1020_CR21","unstructured":"Xe. Currency Converter: USD to TWD.\u00a0Available from: https:\/\/www.xe.com\/currencyconverter\/convert\/?Amount=1&From=USD&To=TWD#:~:text=XE%20Currency%20Converter%3A%201%20USD%20to%20TWD%20%3D%2028.5290%20Taiwan%20New%20Dollars. Accessed 3 June 2020"},{"key":"1020_CR22","unstructured":"National Health Insurance Administration; Ministry of Health and Welfare (2012)\u00a0Health insurance drug item query; denosumab.\u00a0Available from: https:\/\/www1.nhi.gov.tw\/QueryN\/Query1.aspx?n=FC660C5B07007373&sms=36A0BB334ECB4011&topn=3185A4DF68749BA9&upn=80567D1327F69CB9. Accessed 3 June 2020"},{"key":"1020_CR23","unstructured":"National Health Insurance Administration; Ministry of Health and Welfare.\u00a0Available from: https:\/\/www.nhi.gov.tw\/query\/query2.aspx. Accessed 11 Apr\u00a02021"},{"issue":"3","key":"1020_CR24","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s11136-010-9762-x","volume":"20","author":"S Sun","year":"2011","unstructured":"Sun S, Chen J, Johannesson M, Kind P, Xu L, Zhang Y, Burstr\u00f6m K (2011) Population health status in China: EQ-5D results, by age, sex and socio-economic status, from the National Health Services Survey 2008. Qual Life Res 20(3):309\u2013320","journal-title":"Qual Life Res"},{"issue":"3","key":"1020_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00198-017-4317-4","volume":"29","author":"A Svedbom","year":"2018","unstructured":"Svedbom A, Borgst\u00f6m F, Hernlund E, Str\u00f6m O, Alekna V, Bianchi ML, Clark P, Curiel M, Dimai HP, J\u00fcrisson M (2018) Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures\u2014results from the ICUROS. Osteoporos Int 29(3):557\u2013566","journal-title":"Osteoporos Int"},{"key":"1020_CR26","unstructured":"Statistical Bureau; Republic of China (Taiwan) (2019)\u00a0National Statistics\/Statistical Tables.\u00a0Available from: http:\/\/eng.stat.gov.tw\/ct.asp?xItem=37408&CtNode=5347&mp=5. Accessed 1 Dec 2020"},{"issue":"118","key":"1020_CR27","first-page":"124","volume":"93","author":"E Marseille","year":"2015","unstructured":"Marseille E, Larson B, Kazi.S., Kahn J.G., and Rosen S. (2015) Thresholds for the cost\u2013effectiveness of interventions: alternative approaches. Bulletin of the World Health Organization 93(118):124","journal-title":"Bulletin of the World Health Organization"},{"issue":"5","key":"1020_CR28","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s001980170112","volume":"12","author":"J Kanis","year":"2001","unstructured":"Kanis J, Oden A, Johnell O, Jonsson B, De Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12(5):417\u2013427","journal-title":"Osteoporos Int"},{"key":"1020_CR29","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.bone.2013.11.002","volume":"59","author":"A Parthan","year":"2014","unstructured":"Parthan A, Kruse M, Agodoa I, Silverman S, Orwoll E (2014) Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective. Bone 59:105\u2013113","journal-title":"Bone"},{"issue":"sup1","key":"1020_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3111\/13696998.2012.737393","volume":"15","author":"D Chau","year":"2012","unstructured":"Chau D, Becker D, Coombes M, Ioannidis G, Adachi J, Goeree R (2012) Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada. J Med Econ 15(sup1):3\u201314","journal-title":"J Med Econ"},{"issue":"8","key":"1020_CR31","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s00198-007-0349-5","volume":"18","author":"O Str\u00f6m","year":"2007","unstructured":"Str\u00f6m O, Borgstr\u00f6m F, Sen S, Boonen S, Haentjens P, Johnell O, Kanis J (2007) Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries-an economic evaluation based on the fracture intervention trial. Osteoporos Int 18(8):1047\u20131061","journal-title":"Osteoporos Int"},{"issue":"12","key":"1020_CR32","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1007\/s00198-006-0193-z","volume":"17","author":"F Borgstr\u00f6m","year":"2006","unstructured":"Borgstr\u00f6m F, J\u00f6nsson B, Str\u00f6m O, Kanis J (2006) An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting. Osteoporos Int 17(12):1781\u20131793","journal-title":"Osteoporos Int"},{"issue":"1","key":"1020_CR33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bone.2007.10.019","volume":"42","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, Adams J, Borgstr\u00f6m F, Cooper C, J\u00f6nsson B, Preedy D, Selby P, Compston J (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42(1):4\u201315","journal-title":"Bone"},{"key":"1020_CR34","unstructured":"National Health Insurance Administration; Ministry of Health and Welfare. Drug payment regulations.\u00a0Available from: https:\/\/www.nhi.gov.tw\/Content_List.aspx?n=E70D4F1BD029DC37&topn=5FE8C9FEAE863B46. Accessed 11 Apr\u00a02021"},{"key":"1020_CR35","unstructured":"Health Promotion Administration; Ministry of Health and Welfare; Taiwan. Survey results of Chinese smoking behavior.\u00a0Available from: https:\/\/www.hpa.gov.tw\/Pages\/Detail.aspx?nodeid=1718&pid=9913. Accessed 25 Aug 2021"},{"issue":"5","key":"1020_CR36","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/pds.4713","volume":"28","author":"SC Shao","year":"2019","unstructured":"Shao SC, Chan YY, Kao Yang YH, Lin SJ, Hung MJ, Chien RN, Lai CC, Lai ECC (2019) The Chang Gung Research Database\u2014a multi\u2010institutional electronic medical records database for real\u2010world epidemiological studies in Taiwan. Pharmacoepidemiol Drug Saf 28(5):593\u2013600","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-021-01020-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-021-01020-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-021-01020-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T15:07:41Z","timestamp":1642086461000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-021-01020-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,12]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1020"],"URL":"https:\/\/doi.org\/10.1007\/s11657-021-01020-6","relation":{},"ISSN":["1862-3522","1862-3514"],"issn-type":[{"value":"1862-3522","type":"print"},{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,12]]},"assertion":[{"value":"7 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Edward Chia-Cheng Lai received grants from the Ministry of Science and Technology of Taiwan, the Drug Relief Foundation (TDRF) of Taiwan, Hong Kong Community Recovery Fund, Amgen, AbbVie, Taketa, Sanofi, and IQVIA Ltd. Huang-tz Ou received a grant from the Ministry of Science and Technology of Taiwan. Ben Johnson, Hong Li, and Bj\u00f6rn Stollenwerk are employees of Amgen and own Amgen stock.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"155"}}